ASH 2024 Highlights on Multiple Myeloma

CE / CME

CCO’s Conference to Clinic Highlights From ASH 2024 Annual Meeting: Multiple Myeloma

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Nurses: 1.00 Nursing contact hour

Pharmacists: 1.00 contact hour (0.1 CEUs)

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Released: February 11, 2025

Expiration: August 10, 2025

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

A 64-yr-old patient with high-risk smoldering MM is considering early treatment for their disease. What would you tell them about the potential use of daratumumab compared with active monitoring based on the phase III AQUILA trial presented at ASH 2024?

2.

Based on the phase III DREAMM-7 trial presented at ASH 2024, which of the following best describes the expected clinical outcomes for patients with R/R MM treated with belantamab mafodotin plus bortezomib and dexamethasone (BVd) vs daratumumab plus bortezomib and dexamethasone (DVd)?

3.

Which of the following outcomes was reported in the ASH 2024 presentation of the phase I/II CC-92480-MM-002 trial assessing mezigdomide plus either bortezomib/dexamethasone or carfilzomib/dexamethasone in patients with R/R MM?